Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Umibecestat (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Biomarker; Therapeutic Use
- Acronyms GS2
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals
- 04 Aug 2021 Status changed from completed to discontinued.
- 14 Mar 2021 Status changed from discontinued to completed.
- 31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020